Silencing stathmin gene expression by survivin promoter-driven siRNA vector to reverse malignant phenotype of tumor cells

Cancer Biology and Therapy

Volumn 5, Issue 11, 2006, Pages 1457-1461

  Zhang, Hui Zhong ^a   Wang, Yan ^a   Gao, Ping ^a   Lin, Fang ^a   Liu, Li ^a   Yu, Bing ^a   Ren, Ji Hong ^a   Zhao, Hui ^a   Wang, Rui ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Gene therapy; RNA interference; Stathmin; Survivin promoter; Tumor

Indexed keywords

SMALL INTERFERING RNA; STATHMIN; SURVIVIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DRUG DESIGN; DRUG SELECTIVITY; ENDOTHELIUM CELL; EUKARYOTE; EXPRESSION VECTOR; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN CELL; KNOCKOUT GENE; OSTEOSARCOMA CELL; PHENOTYPE; PROMOTER REGION; RNA VECTOR; STAINING; TUMOR CELL; UMBILICAL VEIN; UTERINE CERVIX CANCER;

EID: 33846983923     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.11.3272     Document Type: Article

References (22)

1. Niethammer P, Bastiaens P, Karsenti E. Articles,Stathmin-tubulin interaction gradients in motile and mitotic cells. Science 2004; 303:1862-6.
2. Rubin CI, Atweh GF. The role of stathmin in the egulation of the cell cycle. J Cell Biochem 2004; 93:242-50.
3. Walter-Yohrling J, Cao X, Callahan M, Weber W, Morgenbesser S, Madden SL, Wang C, Teicher BA. Identification of genes expressed in malignant cells that promote invasion. Cancer Res 2003; 63:8939-47.
4. Zhang HZ, Gao P, Yan L, Lin F. Significance of stathmin gene overexpression in osteosarcoma cells. Ai Zheng 2004; 23:493-6.
5. Mistry SJ, Bank A, Atweh GF. Related Articles, Targeting stathmin in prostate cancer. Mol Cancer Ther 2005; 4:1821-9.
6. Baldassarre G, Belletti B, Nicoloso MS, Schiappacassi M, Vecchione A, Spessotto P, Morrione A, Canzonieri V, Colombatti A. Related Articles, p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 2005; 7:51-63.
7. Mistry SJ, Benham CJ, Atweh GF. Development of ribozymes that target stathmin, a major regulator of the mitotic spindle. Antisense Nucleic Acid Drug Dev 2001; 11:41-9.
8. Uprichard SL. Related Articles, The therapeutic potential of RNA interference. FEBS Lett 2005; 579:5996-6007.
9. Dykxhoorn DM, Palliser D, Lieberman J. The silent treatment: siRN As as small molecule drugs. Gene Ther 2006, [Epub ahead of print].
10. Karagiannis TC, El-Osta A. siRNAs: Mechanism of RNA interference, in vivo and potential clinical applications. Cancer Biol Ther 2004; 3:1069-74; Epub 2004 Nov 12. Review.
11. Zaffaroni N, Pennati M, Daidone MG. Survivin as a target for new anticancer interventions. J Cell Mol Med 2005; 9:360-72.
12. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 2005; 92:212-6.
13. Chen JS, Liu JC, Shen L, Rau KM, Kuo HP, Li YM, Shi D, Lee YC, Chang KJ, Hung MC. Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther 2004; 11:740-7.
14. Wu B, Wang Y, Ren JH, Zhao H, Zhang LC, Zhang HZ. Molecular cloning of surviving gene promoter and detecting its specific activity in Hela cell. [J] Chin J Cancer Biother 2005; 12:116-9.
15. Fhemann V, Sykora J, Vera-Delgado J, Lange A, Otto HF. Flow cytometric detetion of spontaneous apoptosis in human breast cancer using the TUNEL-technique. Cancer Lett 2003; 194:125-31.
16. Mistry SJ, Benham CJ, Atweh GF. Development of ribozymes that target stathmin, a major regulator of the mitotic spindle. Antisense Nucleic Acid Drug Dev 2001; 11:41-9.
17. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001; 15:188-200.
18. Tomari Y, Matranga C, Haley B, Martinez N, Zamore PD. A protein sensor for siRNA asymmetry. Science 2004; 306:1377-80.
19. Tiscornia G, Singer O, Ikawa M, Verma I.M. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc Natl Acad Sci USA 2003; 100:1844-8.
20. Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT, Paulson HL, Yang L, Kotin RM, Davidson BL. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 2004; 10:816-20.
21. Kawasaki H, Taira K. Short hairpin type of dsRNAs that are controlled by tRNA(Val) promoter significantly induce RNAi-mediated gene silencing in the cytoplasm of human cells. Nucleic Acids Res 2003; 31:700-7.
22. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004; 23:4051-60.